Anaemia is the most common nutritional deficiency disorder in the world. World Health Organization (WHO) has estimated that prevalence of anaemia in developed and developing countries in pregnant women is 14% and 51%. Its alarming to know that the prevalence in India is as high as 65 to 75%. The search for an ideal parentral iron preparation has led to the introduction of ferric carboxy maltose. It comprises a macromolecular iron-hydoxide complex of polynuclear iron hydroxide tightly bound to a carbohydrate shell. This new complex has a molecular weight of 150,000 Daltons. This design allows for a control leddelivery of iron within the cells of reticulo-endothelial system and hence subsequent delivery to the iron binding proteins, with low risk of release of large amounts of ionic iron in the serum. This iron preparation can be used intravenously in high doses with up to 1000 mg infused within 5 min with minimal risk of side effects.
The objectives of the present study were;
To compare the efficacy of intravenous ferric carboxy maltose with intravenous iron sucrose in treating iron deficiency anaemia in postnatal women.
The mean rise in haemoglobin at the end of one week is an important parameter to evaluate the efficacy of the therapy.
To investigate the safety in terms of local and systemic reactions and tolerability of ferric carboxy maltose compared with iron sucrose.
To compare the cost effectiveness of intravenous iron sucrose and FCM
Type of Study
Randomised Control Study
Period of Study
January 2018-August 2018
Based on the results of this study it is concluded that, the intravenous.
Ferric carboxy maltose is more convenient cost effective in the treatment of puerperal iron deficiency anaemia.
Compared to intravenous iron sucrose. Further it is well. tolerated as side effects are less comparable to that of iron sucrose.